Skip to main content
BioMaxima S.A. logo

BioMaxima S.A. — Investor Relations & Filings

Ticker · BMX ISIN · PLBIOMX00015 LEI · 2594007GAALFMXP4YB89 WAR Manufacturing
Open in API
Filings indexed 616 across all filing types
Latest filing 2025-09-30 Audit Report / Informat…
Country PL Poland
Listing WAR BMX

About BioMaxima S.A.

https://www.biomaxima.com/

BioMaxima S.A. is a manufacturer specializing in in-vitro diagnostics. The company's primary activities include the development and production of a wide range of products for laboratory diagnostics, with a focus on clinical microbiology. Key product categories include microbiological media, various diagnostic reagents, and specialized laboratory equipment. In addition to its manufacturing operations, BioMaxima also serves as a distributor for products from other global diagnostics firms. The company is actively involved in product innovation, including the development of Minimum Inhibitory Concentration (MIC) tests for antibiotic susceptibility testing.

Recent filings

Filing Released Lang Actions
Raport Biegłego z przeglądu sprawozdania skonsolidowanego
Audit Report / Information Classification · 100% confidence The document is a 'Report of the Independent Auditor' (Raport Niezależnego Biegłego Rewidenta) regarding the review of interim condensed consolidated financial statements for BioMaxima S.A. for the period ending June 30, 2025. It explicitly states it is an audit review report (przegląd śródrocznego skróconego skonsolidowanego sprawozdania finansowego) and contains the auditor's conclusion. According to the filing definitions, standalone audit reports and results of regulatory reviews are classified as 'AR'. H1 2025
2025-09-30 Polish
Sprawozdanie Zarządu za I półrocze 2025
Management Reports Classification · 95% confidence The document is a 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for the first half of 2025 for BioMaxima S.A. It contains detailed management commentary, business descriptions, corporate governance information, and operational updates. While it covers the first half of the year, it is structured as a management report (MDA) rather than a full financial statement (IR), although it serves as the narrative component of the interim reporting package. Given the specific category definitions, 'Management Reports' (MDA) is the most accurate classification for this narrative document. H1 2025
2025-09-30 Polish
Skonsolidowane sprawozdanie półroczne ze skróconymsprawozdaniem finansowym
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Skrócone śródroczne skonsolidowane sprawozdanie finansowe' (Condensed Interim Consolidated Financial Statements) for the 6-month period ending June 30, 2025. It contains detailed financial statements, including the statement of profit or loss, statement of financial position, statement of changes in equity, and statement of cash flows, along with extensive explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-30 Polish
List Prezesa Zarządu do akcjonariuszy
Interim / Quarterly Report Classification · 95% confidence The document is a 'Letter to Shareholders' from the CEO of BioMaxima S.A. regarding the financial results for the first half of 2025. It provides substantive financial data, including revenue figures, EBITDA, profit/loss, and detailed analysis of operational costs, margins, and business segments. While it is presented as a letter, it contains the core financial performance analysis typical of an interim report. Given the length and the inclusion of specific financial metrics for the period, it qualifies as an Interim/Quarterly Report (IR). H1 2025
2025-09-30 Polish
Dostawa analizatora - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a short announcement from BioMaxima S.A. regarding a specific commercial contract and delivery of equipment to a client. It does not constitute a full financial report, proxy, or governance document. Since it is a general corporate announcement regarding business operations that does not fit into specific categories like M&A, dividends, or share issues, it falls under the general regulatory announcement category.
2025-09-26 Polish
Informacja o otrzymaniu dofinansowania w kwocie 1.097.835,17 zł na rozbudowę oferty krążków AST - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a corporate announcement from BioMaxima S.A. regarding the successful selection of a project for funding (a grant/subsidy). It details the project's purpose, the amount of funding received, and the strategic impact on the company's product line. Since this is a regulatory announcement regarding company operations and financing/funding updates that does not fit into specific categories like M&A or share issues, it is best classified as a general regulatory filing.
2025-08-27 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.